Robert Zirkelbach Named PhRMA Executive Vice President
Washington, DC (November 15, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Robert Zirkelbach has been named executive vice president of public affairs. Zirkelbach assumes the responsibilities of Josephine Martin, who announced her intent to pursue new opportunities.
“Josie has played a key leadership role in many of PhRMA’s successes in the last five years and has contributed greatly to PhRMA’s evolution into a more forward-leaning organization,” said Stephen J. Ubl, president and chief executive officer of PhRMA. “On behalf of our member companies and our entire staff, I want to thank Josie for her dedication to PhRMA and to our industry.”
A nationally recognized health policy communicator, Zirkelbach has served as senior vice president of communications at PhRMA since 2014. He is responsible for developing and executing the overall communications strategy for the organization and guides multiple high-profile public affairs campaigns on the value of biopharmaceutical innovation, patient access to medicines and other industry priorities. Zirkelbach serves as a lead spokesman for the association and oversees a team that encompasses media relations, digital/social media, advertising, message development, internal communications and executive visibility.
“Since joining PhRMA in 2014, Robby has re-shaped how we as an organization and industry communicate,” said Ubl. “He has built a highly talented team and has repeatedly demonstrated his and his team’s commitment to the highest level of engagement and collaboration with our members and across America’s health care ecosystem.”
Zirkelbach previously served as vice president of strategic communications at America’s Health Insurance Plans. In this capacity, he was the national spokesman for the health insurance industry and played a lead role in crafting the association’s communications strategy and public policy positioning throughout the health care reform debate and implementation of the Affordable Care Act.
“Biopharmaceutical innovation has never been more promising, and it is a privilege to be able to tell the story of what our member companies are doing every day to fight disease,” said Zirkelbach.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.